Last reviewed · How we verify
Dexmedetomidine 2μg.kg-1,1 milliliter
Dexmedetomidine 2μg.kg-1,1 milliliter is a Small molecule drug developed by Xijing Hospital. It is currently FDA-approved.
Dexmedetomidine, marketed by Xijing Hospital, is a 2μg.kg-1, 1 milliliter formulation currently available in the market. The key composition patent for this drug is set to expire in 2028, providing a clear period of exclusivity. The primary risk is the lack of detailed revenue data and key trial results, which may limit strategic planning and investor confidence.
At a glance
| Generic name | Dexmedetomidine 2μg.kg-1,1 milliliter |
|---|---|
| Sponsor | Xijing Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine 2μg.kg-1,1 milliliter CI brief — competitive landscape report
- Dexmedetomidine 2μg.kg-1,1 milliliter updates RSS · CI watch RSS
- Xijing Hospital portfolio CI
Frequently asked questions about Dexmedetomidine 2μg.kg-1,1 milliliter
What is Dexmedetomidine 2μg.kg-1,1 milliliter?
Dexmedetomidine 2μg.kg-1,1 milliliter is a Small molecule drug developed by Xijing Hospital.
Who makes Dexmedetomidine 2μg.kg-1,1 milliliter?
Dexmedetomidine 2μg.kg-1,1 milliliter is developed and marketed by Xijing Hospital (see full Xijing Hospital pipeline at /company/xijing-hospital).
What development phase is Dexmedetomidine 2μg.kg-1,1 milliliter in?
Dexmedetomidine 2μg.kg-1,1 milliliter is FDA-approved (marketed).